Formulations

Among India's largest-volume exports, but the category with the most active enforcement risk.

Mass drug administration programmes buy these in enormous, donation-linked volumes.

A strategic tender category — WHO Prequalification here unlocks Global Fund and Stop TB Partnership procurement.

India's highest-volume export class. Cephalosporins and macrolides move best.

Amphotericin B liposomal and voriconazole are hospital-tender products; topical azoles are high-volume retail lines.

Artemisinin combination therapies are the mainstay; Global Fund, PMI and UNICEF are the dominant buyers.

India supplies the majority of ARVs used in low- and middle-income countries.

Hepatitis C direct-acting antivirals are a landmark Indian export success story.

The deepest and most commoditised class. Margins are thin on older molecules; the growth is in newer anticoagulants and fixed-dose combinations.

A split-personality category: freely exportable antidepressants and antiepileptics alongside NDPS-controlled benzodiazepines.

An accessible entry category with a lower registration burden than orals in several Tier 3 markets.

Insulins and GLP-1s sit under Schedule C/C(1), requiring Form 21B and a validated cold chain.

Proton pump inhibitors are a reliable, high-volume category.

Corticosteroids and thyroid drugs move freely; abortifacient combinations are heavily restricted at both ends.

Heat-stable carbetocin and oxytocin are a genuine Indian strength in maternal-health commodities.

Sterile eye drops need Form 21B and a validated sterile manufacturing line.

Metered-dose and dry-powder inhalers are a specialised manufacturing capability with far less competition than tablets.

Phosphate binders, ESAs and ketoanalogues sell into dialysis chains expanding fast across Africa and SE Asia.